Orient Bio has established a Specific Pathogen Free (SPF) laboratory rabbit production facility in Jeongeup, North Jeolla Province through a technology partnership with Japan’s specialist laboratory animal company Kitayama Labes.


Orient Bio Establishes Laboratory Rabbit Production Facility in Partnership with Japan’s Kitayama Labes View original image

According to Orient Bio on August 4, with the launch of its SPF laboratory rabbit production, the company plans to expand its laboratory animal lineup—previously focused on mice, rats, beagles, and non-human primates—and stably respond to the diverse research demands of domestic universities, research institutes, as well as pharmaceutical and biotechnology companies.


The Jeongeup facility is equipped with an advanced breeding environment and a microbial monitoring system to block the introduction of external pathogens. Strict hygiene management and quality testing are implemented throughout the production process to provide high-quality laboratory animals required for ensuring accuracy and reproducibility in research results.


SPF laboratory rabbits are used in a wide range of life science research, including ophthalmic and dermal irritation tests, as well as in research related to vaccines, biopharmaceuticals, medical devices, immunology, and toxicological assessments. In particular, during non-clinical trials and new drug development, it is crucial to secure laboratory animals in which pathogenic microorganisms and infection factors are strictly controlled.


Orient Bio expects that establishing a domestic production base will reduce uncertainties in supply associated with changes in overseas supply chains, as well as lower the quarantine and transportation burdens that may arise during the import process. This will allow research institutions to receive the laboratory animals they need in a timely manner, thereby improving the stability of research schedules.


The company is currently strengthening its research support system by connecting its laboratory animal production and supply capabilities with non-clinical trial (CRO) services, covering the full process from production and supply to testing and analysis of research animals. Based on this, Orient Bio aims to grow into an integrated bio research solutions company providing comprehensive services needed throughout the bio industry.



An Orient Bio representative said, “We will continue to enhance our research support capabilities from production and supply to non-clinical trials and analysis, growing as a comprehensive bio research solutions company that supports domestic new drug development and the bio research ecosystem. We will also contribute to the advancement of Korea’s non-clinical research and new drug development industry by maintaining internationally recognized quality control and research support expertise.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing